Previous 10 | Next 10 |
Crinetics Pharmaceuticals press release (NASDAQ:CRNX): Q1 GAAP EPS of -$0.73 misses by $0.17. Revenue of $3.13M misses by $2.07M. Unrestricted cash, cash equivalents and investments totaled $319.7 million as of March 31, 2022, compared to $333.7 million as of December 31, 2021. For further ...
Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated Top-Line Data Readouts in 2023 Clinical Trial of CRN04777 in Congenital Hyperinsulinism Patients Planned to...
As a potential big winner, Crinetics Pharmaceuticals executes prudent corporate strategies that focus on orphan diseases and established biological pathways. The lead medicine (paltusotine) demonstrated strong efficacy in its Phase 2 (ACROBAT Edge) trial for acromegaly. I expect s...
Shares have fallen by 15% since my 2019 recommendation. I provide a recap of the bullish thesis and recent events. Endocrinology is a unique field where early-stage studies can achieve substantial degree of 'derisking' in phase 1 healthy volunteer studies. Management & develop...
SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced tod...
5 Top Biotech Stocks To Watch Today The stock market offers plenty of opportunities for investors. Some industries would still catch the attention of investors regardless of the broader market sentiment. A prime example would be biotech stocks . Now, why is that so? For starters...
Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...
Crinetics Pharmaceuticals (NASDAQ:CRNX) has priced an underwritten follow-on offering of 5.63M shares of its common stock at a price to the public of $22.22/share for expected gross proceeds of ~$125.0M. All of the shares to be sold in the offering are to be sold by Crinetics. Offering is exp...
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today t...
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) traded today at a new 52-week high of $41.00. So far today approximately 4.2 million shares have been exchanged, as compared to an average 30-day volume of 264,000 shares. Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is currently priced 2.4% a...
News, Short Squeeze, Breakout and More Instantly...
Crinetics Pharmaceuticals Inc. Company Name:
CRNX Stock Symbol:
NASDAQ Market:
Crinetics Pharmaceuticals Inc. Website:
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its com...
2024-06-25 22:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...